CUSIP: G63637105
Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
21,061,325
-
Share change
-
+8,452,954
-
Total reported value
-
$172,371,190
-
Price per share
-
$8.19
-
Number of holders
-
41
-
Value change
-
+$65,273,296
-
Number of buys
-
34
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP G63637105?
CUSIP G63637105 identifies G63637105 - NABRIVA THERAPEUTICS PLC - SHS in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2017
-
Previous quarter:
Q2 2017
Recent filing periods for CUSIP G63637105:
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS as of Q3 2017
As of 30 Sep 2017,
NABRIVA THERAPEUTICS PLC - SHS was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,061,325 shares.
The largest 10 holders included
Vivo Capital, LLC, ORBIMED ADVISORS LLC, Novo Holdings A/S, WELLINGTON MANAGEMENT GROUP LLP, MORGAN STANLEY, BAKER BROS. ADVISORS LP, Hillhouse Capital Management, Ltd., Alyeska Investment Group, L.P., Marshall Wace North America L.P., and Rock Springs Capital Management LP.
This page lists
41
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.